Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
-
421
Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice.
Published 2013“…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”
-
422
Inflammatory Adipokines Decrease Expression of Two High Molecular Weight Isoforms of Tropomyosin Similar to the Change in Type 2 Diabetic Patients
Published 2016“…The change in expression in HMW isoforms from TPM1 and TPM4 was replicated in THP1 cells treated with 1 ng/ml TNFα (0.10 and 0.12 v 1.00 respectively) or 10 ng/ml IL-1α (0.17 and 0.14 v 1.00 respectively). …”
-
423
-
424
-
425
-
426
-
427
-
428
Data Sheet 1_Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.pdf
Published 2025“…This study investigates the role of the long non-coding RNA GPRC5D-AS1 in the development and progression of sarcopenia through its regulation of SLC7A11. …”
-
429
Supplementary file 1_Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.pdf
Published 2025“…This study investigates the role of the long non-coding RNA GPRC5D-AS1 in the development and progression of sarcopenia through its regulation of SLC7A11. …”
-
430
-
431
Loss of virulence in the SIN kinase mutants is characterized by decreased fungal burden and host response to infection.
Published 2021“…Data are represented as nanograms of <i>A</i>. <i>fumigatus</i> specific DNA in 500 ng of total DNA. * p < 0.02. …”
-
432
-
433
HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching.
Published 2015“…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
-
434
-
435
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
-
436
-
437
-
438
-
439
-
440
A summary of the included study characteristics.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”